Clinical Trial

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Study acronym: ASPENOVA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-20
notable Trial sites expanded: 0 -> 58 locations 2026-05-20
Trial Details
NCT Number NCT07546500
Lead Sponsor K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Conditions Ovarian Cancer
Enrollment 420 participants
Start Date 2026-04-17
Primary Completion 2028-05-31 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12